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Summary
Background: Coronary ﬂow velocity reserve (CFVR) may reﬂect coronary microvascular endothe-
lial function in the absence of signiﬁcant epicardial coronary artery stenosis. The purpose of
this study was to evaluate coronary microvascular endothelial function late (6 and 12 months)
after sirolimus-eluting stent (SES) implantation using transthoracic Doppler echocardiography.
Methods and results: A total of 21 lesions from 21 patients with signiﬁcant left anterior descend-
ing artery stenosis who underwent percutaneous coronary intervention (PCI) with SES were
enrolled and studied. As a control group, 10 patients who were treated with bare metal stent
(BMS) were also studied. CFVR was measured at 6 and 12 months after PCI. Coronary angiogra-
phy was also performed at 6 and 12 months (SES only) after stenting. Between 6 and 12 months
after SES implantation, there was no signiﬁcant difference in angiographical diameter stenosis.
On the other hand, CFVR signiﬁcantly decreased between 6 and 12 months in the SES group
(2.5± 0.5 vs. 2.2± 0.5, p < 0.01), but not in the BMS group (2.3± 0.4 vs. 2.5± 0.3, p = 0.1).
Conclusions: Coronary microvascular endothelial function may deteriorate between 6 and 12
months after SES implantation.
Car© 2010 Japanese College of∗ Corresponding author. Tel.: +81 86 462 1111;
fax: +82 86 462 5200.
E-mail address: miyamo@med.kawasaki-m.ac.jp (Y. Miyamoto).
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ntroductionirolimus-eluting stent (SES) is widely used for percutaneous
oronary interventions because of its excellent long-term
esults with regard to clinical and angiographic outcomes
1]. However, it has been reported that coronary endothe-
Published by Elsevier Ireland Ltd. All rights reserved.
2l
a
a
s
p
t
a
c
c
c
i
l
e
t
M
S
F
w
i
p
s
L
w
r
c
(
b
a
m
w
m
m
i
a
s
g
S
S
S
n
(
a
o
a
a
g
o
b
s
t
t
o
m
o
a
w
d
m
e
l
(
w
u
a
a
w
i
s
o
s
f
T
m
s
r
(
d
d
E
C
f
S
m
a
i
L
i
t
i
i
C
e
C
s
e
C
t
t
L
i
n
t
a
w
s30
ial function distal to the stent may be impaired at 6 months
fter SES implantation [2—4]. Endothelial dysfunction could
ffect long-term clinical outcome, such as stent thrombo-
is, reoccurrence of coronary artery disease due to plaque
rogression, and/or negative vascular remodeling [5,6].
Coronary ﬂow velocity reserve (CFVR) is used as a func-
ional parameter for evaluating the severity of the coronary
rtery stenosis [7]. CFVR also reﬂects coronary microvas-
ular endothelial function in the absence of epicardial
oronary artery stenosis [8].
We hypothesized that SES may affect coronary microvas-
ular endothelial function late (>6 months) after stent
mplantation. To clarify this hypothesis, we assessed the
ong-term effect of SES implantation on microvascular
ndothelial function as assessed by CFVR using serial
ransthoracic Doppler echocardiography.
ethods
tudy population
rom January 2004 to March 2007, a total of 136 patients
ho had stable angina pectoris with left anterior descend-
ng artery (LAD) disease and underwent successful elective
ercutaneous coronary intervention with either bare metal
tent (BMS, n = 40) or SES (n = 96, Cypher, Cordis Corp., Miami
akes, FL, USA) were included in this study. Exclusion criteria
ere as follows: (1) acute myocardial infarction; (2) stent
estenosis lesion; (3) bifurcation lesions; (4) symptomatic
ongestive heart failure; (5) severe valvular heart disease;
6) history of coronary spasm; (7) history of coronary artery
ypass surgery. Risk factors for endothelial dysfunction such
s dyslipidemia, left ventricular (LV) hypertrophy, diabetes
ellitus, and smoking were assessed. Coronary angiography
as repeated at 6 months (both SES and BMS) and at 12
onths (SES only) after stent implantation. CFVR could be
easured in 65 of 136 patients (48%) at 6 months after stent
mplantation (45 in the SES group and 20 in the BMS group)
nd in 31 of 65 patients (48%) patients at 12 months after
tent implantation (21 in the SES group and 10 in the BMS
roup). Finally, a total of 31 patients who were treated with
ES (n = 21) or BMS (n = 10) were enrolled in this study.
tudy protocol
tent implantation was performed using standard tech-
iques. Before the procedure, an intravenous heparin bolus
100 IU/kg) was administered. Before coronary angiography,
ll of the patients received an intracoronary bolus injection
f nitroglycerin. In all patients, the stents were implanted
fter pre-dilation procedure. The pre-dilation site and the
therosclerotic lesions were fully covered to avoid geo-
raphic miss [9]. Post-dilation was performed if necessary,
nly in the in-stent area using a quarter- or half-size up
alloon. No patient required balloon dilation beyond the
tent margins, avoiding balloon-induced vessel injury. Mul-
iple stent implantations were done if necessary to cover
he entire diseased segment and in such cases, a minimum
verlapping portion up to 1mm between stents was recom-
ended. After stent placement, 21 patients with SES were
n dual antiplatelet regimen of ticlopidine (200mg/day) and
i
a
s
m
sY. Miyamoto et al.
spirin (100mg/day) for at least 3 months. Ten patients
ith BMS were on dual antiplatelet regimen of ticlopi-
ine (200mg/day) and aspirin (100mg/day) for at least 1
onth. Blood chemistry data [total cholesterol (TC), triglyc-
rides (TG), high-density lipoprotein-cholesterol (HDL-C),
ow-density lipoprotein-cholesterol (LDL-C), hemoglobin A1c
HbA1c), and C-reactive protein (CRP)] were evaluated
ithin 3 days before stent implantation, and at the follow-
p coronary angiography. Follow-up coronary angiography 6
nd 12 months after stent implantation was performed 1 day
fter CFVR measurements.
Off-line quantitative analysis of coronary angiography
as performed with the CAAS II system (Pie Medical Imag-
ng, Maastricht, the Netherlands), blinded to knowledge of
tent type. Minimal luminal diameter (MLD) and diameters
f the reference segments were measured before and after
tenting and at 6- and 12-month follow-up from diastolic
rames in a single, matched view showing the smallest MLD.
he target lesion MLD included the stent as well as 5mm
argins proximal and distal to the stent. The reference ves-
el diameter was the average of the proximal and distal
eference lumen diameters. The percent diameter stenosis
%DS) was obtained by dividing the minimal diameter of the
iseased segment by the diameter of an adjacent proximal
isease-free section.
chocardiographic measurement
omprehensive two-dimensional echocardiography was per-
ormed using an ACUSON Sequoia 512 (Siemens Medical
olutions USA Inc., Mountain View, CA, USA) at 6 and 12
onths after stent implantation. Recordings were obtained
t rest according to the recommendations of the Amer-
can Society of Echocardiography. Measurements included
V dimension at diastole (LVDd), LV dimension at systole,
nterventricular septal thickness (IVST), and posterior wall
hickness (PWT). LV ejection fraction (LVEF) was calculated
n the 4-chamber view usingmodiﬁed Simpson’s rule. LVmass
ndex (LVMI) was calculated as reported previously [10].
FVR measurements by transthoracic Doppler
chocardiography
FVR measurements were performed using the same ultra-
ound system with a 7V2C probe. For color Doppler
chocardiography, the velocity range was set at 12—24 cm/s.
olor and pulsed-wave Doppler studies were performed in
he fundamental imaging mode at 2.5 and 2.0MHz, respec-
ively. First, we recorded baseline Doppler signals in the
AD. Next, adenosine triphosphate (0.14mg kg−1 min−1) was
nfused intravenously for 2min to achieve maximal coro-
ary hyperemia. CFVR was deﬁned as the ratio of hyperemic
o basal mean diastolic velocity (MDV). Measurements were
veraged over 3 cardiac cycles. Two independent observers
ho were unaware of the patients’ data performed all mea-
urements. Heart rate and blood pressure were monitored
n both conditions. Mean blood pressure was calculated
s: (systolic pressure−diastolic pressure)/3 + diastolic pres-
ure. Any medications that may affect coronary ﬂow
easurements were discontinued >24 h before the Doppler
tudy. The intra-observer and inter-observer variabilities of
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Table 1 Patient characteristics and baseline data.
SES group (n = 21) BMS group (n = 10) p-Value
Age (years) 70± 11 67± 10 0.48
Male, n 12 (57%) 6 (60%) 0.99
Hypertension, n 19 (90%) 9 (90%) 0.99
Dyslipidemia, n 11 (52%) 8 (80%) 0.24
Diabetes, n 11 (52%) 4 (40%) 0.70
Smoking, n 11 (52%) 3 (30%) 0.28
SVD/MVD, n 12/9 6/4 0.99
Previous myocardial infarction, n 4 (19%) 1 (10%) 0.99
Unstable angina pectoris, n 3 (14%) 7 (70%) <0.01
Stable angina pectoris, n 18 (86%) 3 (30%) <0.01
Statin use, n 14 (67%) 9(90%) 0.22
ACE inhibitor/ARB inhibitor use, n 13 (62%) 10(100%) 0.03
Left ventricular hypertrophy,a n 7 (33%) 6 (60%) 0.25
TC, mg/dl 192.8± 37.7 206.2± 41.8 0.38
TG, mg/dl 118.0 (84.5—185.0) 115.5 (83.0—184.0) 0.77
HDL-C, mg/dl 44.2± 10.0 46.5± 15.1 0.62
LDL-C, mg/dl 122.3± 36.7 135.0± 28.5 0.35
Hemoglobin A1c (%) 6.0± 0.9 6.3± 1.7 0.58
Data are presented as the mean value± SD, the median (interquartile range) or number (%) of patients. SES, sirolimus-eluting stent;
BMS, bare metal stent; SVD, single-vessel coronary artery disease; MVD, multivessel coronary artery disease; ACEI, angiotensin-converting
enzyme inhibitor; ARB, angiotensin receptor blocker; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein-cholesterol;
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a Standard for detection of left ventricular hypertrophy in a hete
ventricular mass index of 110 g/m2 or greater for women and 134
mean diastolic velocity-derived coronary ﬂow reserve (CFR)
measurements have been low [11,12]. CFR is an index to
show the ability to increase coronary blood ﬂow for the
enhancement of myocardial oxygen demand.
Statistical analysis
Data are expressed as the mean± SD, median, and
interquartile range (25%; 75%). Unpaired t test was per-
formed to compare the data in the BMS group and the SES
group. Paired t tests were performed to compare the data
at baseline and after stent implantation of both groups. A
p-value of <0.05 was considered to be statistically signif-
icant. Analyses were performed in part with StatView 5.0
(SAS Institute, Cary, NC, USA).
Results
Study population
Thirty-one patients were included in this study (21 in the
SES group and 10 in the BMS group). During 12 months fol-
lowing the index procedure, none of the study patients had
restenosis, target lesion restenosis, or stent thrombosis.
Patient characteristics during observation periodThe baseline characteristics of the subjects are shown in
Table 1. Coronary risk factors were equally distributed in the
SES and BMS groups. Five patients (4 in the SES group and 1 in
the BMS group) had a previous history of myocardial infarc-
I
e
b
mneous urban population utilizes sex-speciﬁc cutoff values for left
or greater for men.
ion in the non-LAD territory. Ten patients (3 in the SES group
nd 7 in the BMS group) had unstable angina pectoris. There
ere no statistically signiﬁcant differences in the baseline
haracteristics including age, gender, and coronary risk fac-
ors. Angiotensin-converting enzyme (ACE) inhibitors and
ngiotensin receptor blockers (ARBs) were more frequently
sed in the BMS group; otherwise medications were similar
etween the two groups.
The angiographic and procedural characteristics are
hown in Table 2. Quantitative coronary angiographic anal-
sis showed no differences in pre- and post-procedural
arget lesion characteristics. Stent length tended to be
onger in the SES group than the BMS group (20.4± 4.4 vs.
7.7± 5.5mm; p = 0.15), although it did not reach statisti-
al signiﬁcance. Tables 3—5 show hemodynamic, laboratory,
nd transthoracic echocardiography data in both groups at
and 12 months after stent implantation. Systolic and dias-
olic blood pressure, HbA1c, and LVMI were similar between
and 12 months in both groups. HDL-C at 12 months was
igniﬁcantly lower than at 6 months in the SES group. Oth-
rwise, lipid levels were similar between 6 and 12 months
fter stent implantation in both groups. Preprocedural and
ost-procedural %DS did not differ between the SES and BMS
roups.
FVR and hemodynamic data between 6 and 12
onths after stent implantationn the SES group, there was no signiﬁcant differ-
nce in mean arterial pressure and heart rate at
aseline and during hyperemia between 6 and 12
onths (109.4± 21.5 vs. 105.0± 32.5mmHg, p = 0.99,
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Table 2 Quantitative coronary angiographic results.
SES group (n = 21) BMS group (n = 10) p-Value
Lesion length, mm 11.2 ± 4.6 9.6 ± 3.5 0.34
RVD, mm
Pre-procedural 2.47 ± 0.63 2.19 ± 0.38 0.21
MLD, mm
Pre-procedural 0.90 ± 0.30 0.78 ± 0.17 0.46
Post-procedural 2.24 ± 0.37 2.15 ± 0.39 0.55
%DS
Pre-procedural 65.1 ± 11.2 63.8 ± 6.3 0.88
Post-procedural 15.9 ± 4.4 16.1 ± 6.5 0.92
Stent diameter, mm 2.83 ± 0.24 2.90 ± 0.29 0.50
Stent length, mm 20.4 ± 4.4 17.7 ± 5.5 0.15
Data are presented as the mean value± SD or number (%) of patients. SES, sirolimus-eluting stent; BMS, bare metal stent; RVD, reference
vessel diameter; MLD, minimal lumen diameter; %DS = percent diameter stenosis.
Table 3 Hemodynamic and laboratory data characteristics within the SES and BMS groups.
SES group (n = 21) BMS group (n = 10)
6 months 12 months 6 months 12 months
Systolic BP, mmHg 133± 15 129± 15 126± 12 131± 12
Diastolic BP, mmHg 68± 11 69± 10 67± 8 70± 8
Heart rate, min−1 71± 10 69± 9 65± 5 68± 16
Hemoglobin, g/dl 13.5± 1.7 13.2± 1.9 12.6± 2.4 13.7± 1.4
Hemoglobin A1c, % 5.9± 0.9 5.9± 0.7 6.0± 1.1 6.0± 0.9
Glucose, mg/dl 118.0± 43.4 125.3± 48.6 104.6± 19.8 128.8± 67.8
TC, mg/dl 177.4± 34.2 181.7± 38.4 163.1± 31.5 174.7± 35.2
TG, mg/dl 117.5 (88.0—167.0) 130 (103.0—148.3) 119.0 (87.0—141.0) 93.0 (87.5—121.9)
HDL-C, mg/dl 48.3± 10.7 46.3± 11.5 49.0± 11.8 49.0± 12.3
LDL-C, mg/dl 104.7± 33.1 106.3± 29.1 93.4± 23.0 104.1± 27.1
Creatine, mg/dl 0.77± 0.14† 0.78± 0.14 1.3± 1.0 1.4± 1.5
CRP, mg/dl 0.07 (0.05—0.10) 0.07 (0.05—0.16) 0.07 (0.04—0.11) 0.05 (0.03—0.07)
Data are presented as the mean value± SD, the median (interquartile range). SES, sirolimus-eluting stent; BMS, bare metal stent;
BP, blood pressure; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein
cholesterol; CRP, C-reactive protein.
† p < 0.05 vs. BMS group.
Table 4 Transthoracic echocardiography characteristics at 6 and 12 months after SES and BMS.
SES group (n = 21) BMS group (n = 10)
6 months 12 months 6 months 12 months
LVDd, mm 43.2± 4.3 42.0± 5.5 42.1± 5.7 43.7± 3.5
LVDs, mm 27.8± 4.4† 26.1± 6.3 23.4± 5.7 25.0± 4.4
IVST, mm 11.1± 2.4 11.2± 2.6 12.6± 4.1 12.3± 4.0
PWT, mm 11.1± 2.0 10.7± 2.2 11.7± 2.8 11.8± 3.0
LVEF, % 61.6± 6.1 64.9± 6.8 62.4± 7.7 63.9± 6.9
LVMI, g/m2 120± 26 107± 30 135± 50 143± 58
LVH, n 8 (38) 9 (43) 5 (50) 7 (70)
Data are presented as the mean value± SD or number (%) of patients. SES, sirolimus-eluting stent; BMS, bare metal stent; LVDd, left ven-
tricular end-diastolic diameter; LVDs, left ventricular end-systolic diameter; IVST, interventricular septum thickness; PWT, left ventricular
posterior wall thickness; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index; LVH, left ventricular hypertrophy.
† p < 0.05 vs. BMS group.
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Table 5 CFVR and QCA characteristics at 6 and 12 months after SES and BMS.
SES group (n = 21) p-Value BMS group (n = 10) p-Value
6 months 12 months 6 months 12 months
Rest
Heart rate, min−1 61.1 ± 10.3 64.5 ± 9.3 0.42 64.9 ± 15.0 64.0± 8.8 0.79
MAP, mmHg 109.4 ± 21.5 105.0 ± 32.5 0.99 106.4 ± 20.6 106.9± 15.7 0.87
MDV, cm/s 16.2 ± 5.4 15.9 ± 5.8 0.64 19.2 ± 8.0 17.0± 6.7 0.57
Hyperemia
Heart rate, min−1 69.7 ± 11.6 73.9 ± 13.6 0.70 73.0 ± 16.4 74.4± 15.7 0.40
MAP, mmHg 97.5 ± 28.0 94.1 ± 19.7 0.93 97.4 ± 16.2 98.3± 14.2 0.45
MDV, cm/s 41.7 ± 16.3 32.5 ± 9.9† 0.02 44.2 ± 20.3 42.7± 15.7 0.87
CFVR 2.5 ± 0.5 2.2 ± 0.5† <0.01 2.3 ± 0.4 2.5± 0.3 0.11
DS, % 15.6 ± 7.5 14.2 ± 6.3 0.53 18.5 ± 6.3 NA NA
locity reserve; QCA, quantitative coronary angiography; SES, sirolimus-
MAP, mean arterial pressure; NA, not available; DS, diameter stenosis.
F
b
vData are presented as the mean value± SD. CFVR, coronary ﬂow ve
eluting stent; BMS, bare metal stent; MDV, mean diastolic velocity;
† p < 0.05 vs. BMS group.
61.1± 10.3 vs. 64.5± 9.3min−1, p = 0.42, 97.5± 28.0
vs. 94.1± 19.7mmHg, p = 0.93, and 69.7± 11.6 vs.
73.9± 13.6min−1, p = 0.70). Baseline MDV did not change
between 6 and 12 months after stent implantation
(16.2± 5.4 vs. 15.9± 5.8 cm/s, p = 0.64). Hyperemic MDV
was signiﬁcantly decreased at 12 months after stent
implantation (6 months: 41.7± 16.3 vs. 12 months:
32.5± 9.9 cm/s, p < 0.05). As a result, CFVR signiﬁcantly
decreased between 6 and 12 months (2.5± 0.5 vs. 2.2± 0.5,
p < 0.01) (Fig. 1) (Table 5).
In the BMS group, on the other hand, there was no
signiﬁcant difference in mean arterial pressure and heart
rate at baseline and during hyperemia between 6 and
12 months (106.4± 20.6 vs. 106.9± 15.7mmHg, p = 0.87,
64.9± 15.0 vs. 64.0± 8.8min−1, p = 0.79, 97.4± 16.2
vs. 98.3± 14.2mmHg, p = 0.45, and 73.0± 16.4 vs.
74.4± 15.7min−1, p = 0.40). CFVR tended to increase
between 6 and 12 months after stent implantation
(2.3± 0.4 vs. 2.5± 0.3, p = 0.11) (Fig. 2), although the
difference did not reach statistical signiﬁcance (Table 5).
Although CFVR in the SES group showed a trend toward
being higher than in the BMS group at 6 months (2.5± 0.5
Figure 1 Coronary ﬂow velocity reserve (CFVR) change
between 6 and 12 months after sirolimus-eluting stent.
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digure 2 Coronary ﬂow velocity reserve change (CFVR)
etween 6 months and chronic phase after bare metal stent.
s. 2.3± 0.4, p = 0.13), CFVR in the SES group was signiﬁ-
antly lower than in the BMS group (2.2± 0.5 vs. 2.5± 0.3,
= 0.03) at 12 months after stent implantation.
ngiographic follow-up at 6 and 12 months
n the SES group, there was no signiﬁcant difference in angio-
raphical diameter stenosis between 6 and 12 months after
tent implantation (15.6± 7.5% vs. 14.2± 6.3%, p = 0.53)
Table 5).
iscussion
he principal ﬁnding of this study was that CFVR signif-
cantly decreased between 6 and 12 months after SES
mplantation despite preserved epicardial coronary lumen,
uggesting that coronary microvascular endothelial function
ay deteriorate late (>6 months) after SES implantation.
revious studies have repeatedly shown that SES implanta-
ion was associated with prolonged endothelial dysfunction
2,3,13,14]. Maekawa et al. reported severe endothelial dys-
unction in the SES at 6 months after stenting, suggesting
elayed reendothelialization with inadequate endothelial
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overage in the long SES [15,16]. In addition, it has been
eported that exercise-induced coronary vasoconstriction
ay occur in the vessel segments adjacent to SES but not
MS [4]. Our present results not only support the previous
eports but also address the fact that SES may further affect
icrovascular endothelial function even beyond 6 months
fter SES implantation.
In our present study, decreased CFVR in the SES group
eems unrelated to the epicardial coronary artery steno-
is, because coronary angiography at 12 months did not
how any in-stent lumen narrowing or de novo lesion pro-
ression. Therefore, decreased CFVR in the SES group does
urely reﬂect coronary microvascular dysfunction. Although
ngiography was not repeated at 12 months in patients
reated with BMS, it is unlikely that in-stent restenosis devel-
ped because CFVR did not change or marginally improved
ver time. Previous angiography and IVUS studies have
emonstrated that in-stent neointimal regression rather
han progression is observed between 6 months and 1—3
ears after BMS implantation [17,18]. Therefore, it is pos-
ible that the favorable trend in CFVR observed in the BMS
roup was a result of improved luminal narrowing.
CFVR may be inﬂuenced by a number of clinical and
emodynamic parameters such as hypertension, diabetes
ellitus, LV systolic function [19], and LV hypertro-
hy [20—22]. Hemodynamics during adenosine infusion,
emoglobin concentration, and medical treatments were all
nchanged between 6 and 12 months. Interestingly, lipid
roﬁle and severity of diabetes mellitus, both of which may
egatively affect CFVR, were improved between 6 and 12
onths. Therefore, it is unlikely that these clinical factors
ffected our results. In this study, CFVR was decreased as
result of decreased hyperemic MDV, rather than increased
aseline MDV, suggesting coronary microcirculation dysfunc-
ion.
There are several possible causes by which coronary
icrovascular dysfunction developed late (12 months)
fter SES implantation. First, it is possible that sirolimus
rapamycin) itself affected coronary microcirculation. How-
ver, SES is designed in such a way that ∼80% of the
apamycin has eluted by 30 days [1]. It is, therefore, unlikely
hat the drug could directly affect microvascular endothelial
unction between 6 and 12 months after SES implantation.
Second, vascular inﬂammatory response to the polymer
ight be related to the coronary microcirculatory dysfunc-
ion. Although, SES appears to reduce the periprocedural
nﬂammatory response, as compared with BMS, pathologi-
al studies have demonstrated peri-stent local inﬂammatory
esponse to the SES at follow-up. Recently, several animal
xperiments demonstrated that durable polymer (cypher-
olyethylene-co-vinyl acetate [PEVA] and poly n-butyl
ethacrylate [PBMA]) provoke eosinophilic/heterophilic
nﬁltration of the arterial wall (unpublished data, 2006
inn). The relationship between chronic inﬂammation and
ndothelial dysfunction is well known [23,24] and, there-
ore, the inﬂammatory response to the polymer late after
ES implantation may be one possible cause of microvascular
ndothelial dysfunction after SES implantation [3,25].
Third, pathological and angioscopical investigations have
hown that thrombus (ﬁbrin) is more frequently found after
ES implantation than BMS [25,26]. Another angioscopi-
al study of patients with acute coronary syndrome hasY. Miyamoto et al.
uggested that patients with ﬁbrin detected by coronary
ngioscopy have higher incidence of elevated troponin T
evel during the convalescent period after the onset of the
cute coronary syndrome, suggesting that ﬁbrin thrombus
ttached to the SES might be liberated and possibly resulted
n coronary microembolization and thus microvascular dys-
unction [27].
Therefore, it is possible that thrombus formation at the
ite of the SES uncovered by the neointimamay be the source
f microvascular embolization and, therefore, the cause of
icrovascular endothelial dysfunction. Whether prolonged
ual antiplatelet therapy will preserve coronary microvas-
ular endothelial function needs to be investigated.
imitations
irst, our study is limited by the small sample size and a non-
andomized design to select the type of stents. Therefore,
nknown confounding factors might have contributed to the
ifferences between the SES and BMS groups. Similarly, our
esults do not provide impact of the impaired CVFR on long-
erm clinical outcome (more than 12 months).
Second, ACE inhibitors/ARBs were more frequently pre-
cribed in the BMS group. ACE inhibitors and ARBs have been
eported to improve endothelial function [28—30], which
ight affect CFVR as well.
Third, we used adenosine triphosphate to inducemaximal
yperemia in this study because microvascular endothelial
unction could be assessed non-invasively by transtho-
acic echocardiography. However, it has been reported
hat acetylcholine might be more appropriate to test a
ure endothelial-dependent vasomotor response through
NOS.
onclusions
oronary microvascular endothelial function may deteri-
rate between 6 and 12 months after SES implantation.
ong-term impact of the late microvascular impairment
fter SES implantation on clinical outcome needs to be inves-
igated.
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